Home
About
Overview
Sharing Data
ORCID
Help
History (1)
EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study.
EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. J Hepatol. 2022 03; 76(3):506-517.
View in:
PubMed
subject areas
Administration, Oral
Adult
Analysis of Variance
Canada
Dose-Response Relationship, Drug
Double-Blind Method
Female
France
Germany
Humans
Liver
Male
Middle Aged
New Zealand
Non-alcoholic Fatty Liver Disease
Placebos
Receptors, Cytoplasmic and Nuclear
Steroids
Treatment Outcome
United Kingdom
United States
authors with profiles
Mary Rinella